ABSTRACT. Patients with cystic fibrosis and pancreatic sufficiency were investigated for evidence of progressive pancreatic disease. From a cohort of 630 patients, 20 pancreatic-sufficient patients became pancreatic insufficient after an average duration of 5.6 y (range 0.6-20.6 y) from diagnosis. Among 54 patients documented to be pancreatic sufficient by direct pancreatic stimulation test, 47 remained pancreatic sufficient and seven developed pancreatic insufficiency. The patients who ultimately developed pancreatic insufficiency were younger and had greatly reduced outputs of enzyme, fluid, and electrolytes. Those who remained pancreatic sufficient showed enzyme secretion close to or within the non-cystic fibrosis control range. Twenty of these patients underwent a second pancreatic stimulation test after an average interval of 4 y (range 1.3-6.2 y). No significant alteration in enzyme, fluid, or electrolyte output was seen in the patients who remained pancreatic sufficient, but there was further reduction in enzyme and fluid output in the patients who developed pancreatic failure. In conclusion, the majority of pancreatic-sufficient patients with pancreatic enzyme secretion within the control range showed no deterioration of function over an extended time period. However, a small number of pancreatic-sufficient patients with reduced enzyme and fluid secretion are at risk of pancreatic failure. (Pediatr Res 32: 179-182, 1992) in CF neonates diagnosed by newborn screening reveal that 38% of CF infants are pancreatic sufficient at diagnosis (3), but 21% of these patients develop pan creatic insufficiency between 3 and 36 mo of age. This observation supports the previous suggestion that some pancreatic-sufficient patients will develop pancreatic insufficiency with advancing age. Also, in nonscreened populations , the variable age of diagnosis and modes of clinical presentation may be attributed to varying onset of signs and symptoms of pancreatic failure.There are few data concerning longitudinal changes of exocrine pancreatic function in patients with pancreatic sufficiency. Our current cross-sectional data suggest that pancreatic-sufficient patients are capable of secreting adequate amounts of pancreatic enzymes to ensure normal digestion, but it is important to emphasize that this subgroup of CF patients is characterized by a wide range of acina r capability, from mean values similar to control subjects to enzyme secretory rates as low as I to 2% of the mean normal rate (4). The wide variation of exocrine pancreatic function in pan creatic-sufficient patients together with the fact that these parti cular patients are prone to recurring attacks of acute pancreatitis (5) strongly suggest that ongoing pancreatic damage occurs . To evaluate this possibility, we have assessed pancreatic-sufficient patients for evidence of progressive pancreatic disease and have attempted to characterize those at risk of developing pancreatic failure.
Abbreviations PATIENTS AND METHODS